Agenda for Day 2 - Wednesday December 9, 2026 - CST/CDT (Central Daylight, GMT-5)
- Grant Knowles - Senior Vice President of Clinical Services and Payer Strategies, SenderraRX
- Deconstruct PBA vs PBM: real differentiation vs marketing language
- Evaluate admin fee and fee-for-service models under cost pressure
- Identify which models hold up operationally and financially
- Jessin Joseph - Vice President, PBA Markets, Judi Health
- Dominic Adducci - Former Director, Pharmacy Pricing & Growth, Blue Shield of California
- Deb Curry, PharmD - Chief Strategy & Operations Officer, Health Delegates
- Jeff Griggs - Senior Principal, Consultant Relations, Prime Therapeutics
Hear from a PBM and a physician on why unrecognized menopause symptoms are quietly draining workforce productivity, and how smarter benefit design can turn that cost into a measurable return.
Define the true cost of untreated perimenopause and menopause, from quiet absenteeism to the loss of experienced mid-career women employers can't afford to lose.
Tackle the misdiagnosis problem, showing how symptoms like fatigue, brain fog, and weight changes get blamed on everything except menopause, delaying treatment and inflating downstream claims.
Understand the biology behind midlife weight gain and how evidence-based menopause care, including hormone therapy, can work alongside GLP-1 coverage for a smarter, outcomes-driven strategy.
Equip plan sponsors with a clear ROI framework for recognizing and coding menopause care, helping justify coverage decisions even when short-term savings are hard to quantify.
- Caissa Troutman, MD - Founder & Physician, Midlife reMDy
- Barbara Rambo - CEO, ProCare Rx
As employers seek greater control over pharmacy spend, some are exploring in-house or tightly aligned pharmacy models. This session evaluates whether these approaches represent a meaningful shift or a limited-use strategy.
Define in-house, near-site, and employer-aligned pharmacy dispensing models
Compare cost, control, and flexibility versus traditional PBM structures
Examine how direct contracting and alternative dispensing channels can reshape pharmacy benefit management
Assess where these models are viable across different employer sizes, populations, and infrastructures
Explore operational, financial, and regulatory considerations when implementing employer-led pharmacy strategies
Evaluate whether these approaches can improve member experience, reduce conflicts of interest, and deliver measurable savings
- Zac Hanson - VP, Growth, RxPreferred Benefits
- Gordon Romanas - Senior Vice President, Bayvrio
- Ryan Baker - Senior Vice President, Pharmacy, Premise Health
- Evaluate eligibility and access strategies for high-cost therapies, including GLP-1s
- Assess biosimilar adoption dynamics (e.g., Humira, Stelara)
- Compare PBM vs health plan strategies and real-world case studies
- Analyze trade‑offs between high‑cost/high‑rebate and low‑cost/low‑rebate drug pricing models
- Examine the use of PBM–or retailer–sponsored branded biosimilars as preferred formulary options
- Nate Harold, PharmD, RPh - Chief Pharmacy Officer, MedOne Pharmacy Benefit Solutions
- Ernesto Munoz, PharmD, MBA, CEBS - Clinical Advisor, Employers Health
- Grant Knowles - Senior Vice President of Clinical Services and Payer Strategies, SenderraRX
- Alam Hallan - Chief Technology Officer, Thor Health
- Analyze how employer demand shapes PBM models and pricing
- Evaluate preference for “easy button” solutions vs customized strategies
- Examine role of HRSA plans and intersection with state legislation
- Matthew Lee - Vice President - Sales & Marketing, MedOne Pharmacy Benefit Solutions
- Barbara Rambo - CEO, ProCare Rx
As employers increasingly rely on brokers and consultants to evaluate PBMs, differentiation is no longer defined by what PBMs claim—but by how those claims are interpreted, filtered, and prioritized in broker-led decision processes. This session examines how PBMs position themselves in a crowded market—and how brokers and employers assess those differences in practice.
- Identify what PBMs position as differentiation: transparency, pricing models, clinical programs, and technology
- Examine how brokers structure RFPs and vendor comparisons—and what actually stands out
- Where vendor commitments break down, including exclusions and loss of transparency
- Evaluate whether newer models (PBA, disaggregated, fee-for-service) represent meaningful differentiation or repackaging
- Assess where PBMs fail to differentiate in ways that matter to employers
- Explore how employers interpret broker guidance—and where misalignment occurs
- Justin Jasniewski - Chief Executive Officer, ServeYouRx
- Richard Wipperfurth - Chief Commercial Officer, Welldyne
- Will disruptors persist or be absorbed?
- How will GLP-1 pricing and MFP reshape contracting?
- Which PBM models survive regulatory and employer pressure?
- What breaks first: margins, access, or network stability?
- David Schryver, PharmD - President, ProAct
- Andrew York, Pharm.D., J.D. - Executive Director, Maryland Prescription Drug Affordability Board
- Sophie Thomas - PBM Enforcement Director, Colorado Department of Regulatory Agencies
